Subsequently, the GR agonist dexamethasone (Dex) was administered intrathecally to confirm whether depression-induced nociceptive alternations were mediated by spinal GRs and whether BDNF signaling was modulated by GRs in this situation. This evidence concerns the gene BCL2A1 and depressive symptom measurement.